Table 1_Concurrent moxifloxacin-induced liver injury and toxic epidermal necrolysis after immune checkpoint inhibition: a case report and literature review.docx

A medical case report details a 58-year-old male patient with lung adenocarcinoma who developed synchronous drug-induced liver injury and toxic epidermal necrolysis after moxifloxacin treatment post-immune checkpoint inhibitor therapy. The document includes a systematic review of 28 published cases of concurrent DILI and SJS/TEN. It was authored by Qiangsheng Li and published in March 2026.

Use Cases

• Analyze the RUCAM and ALDEN causality assessment scores from the case report to study moxifloxacin's role in adverse events.
• Extract drug classes and clinical features from the systematic review of 28 cases to identify patterns in concurrent DILI and SJS/TEN.
• Identify patient demographics and treatment history (e.g., lung adenocarcinoma, neoadjuvant tislelizumab) for cohort studies on immunotherapy-related risks.
• Review the documented timeline (e.g., ten days post-moxifloxacin initiation) for modeling the onset of severe adverse drug reactions.

Strengths

• Includes a systematic review of 28 published cases of concurrent DILI and SJS/TEN.
• Provides detailed clinical causality assessments using RUCAM (score 9) and ALDEN (score 5) methodologies.
• Document is recent, last updated in March 2026.

Limitations

• The core data is a single case report, offering limited statistical power for generalization.
• Available as a DOCX file (1.1 MB), requiring text extraction for structured analysis.
• No structured tabular data or defined columns are provided, limiting direct computational use.

Provenance

Source

figshare, authored by Qiangsheng Li.

Collection Method

Clinical case documentation and systematic literature review.

Time Range

Case event timeline and literature review period not specified.

Freshness

Last updated March 2026.

Geography

Geographic origin of the case and reviewed literature not specified.